公开(公告)号：US20240360137A1

公开(公告)日：2024-10-31

申请号：US18442235

申请日：2024-02-15

Applicant: Novartis AG

Inventor： Karin BRINER ,  Xin CHEN ,  Sajan JOSEPH ,  Vivek RAUNIYAR ,  Frédéric ZECRI

IPC: C07D487/04 ,  A61K31/519 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/519 ,  C07D519/00

Abstract: The invention relates to compounds which inhibit CDK2 (Cyclin-Dependent Kinase 2 or Cell Division protein Kinase 2), and to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by CDK2.

公开(公告)号：US20250092016A1

公开(公告)日：2025-03-20

申请号：US18580986

申请日：2022-07-20

Applicant: NOVARTIS AG

Inventor： Denghui BAO ,  Fengfeng GUO ,  Matthew James HESSE ,  Viktor HORNAK ,  Sajan JOSEPH ,  Thomas Martin KIRRANE, JR. ,  Haiyao LIN ,  Bo LIU ,  Yanan MIAO ,  Heinz Ernst MOSER ,  Julien PAPILLON ,  Yang QU ,  Lei SHI ,  Jun YUAN ,  Teng ZHANG

IPC: C07D401/14 ,  A61K31/4725 ,  A61K31/501 ,  A61K31/506 ,  A61P31/14 ,  C07D401/04

Abstract: Provided herein are compounds and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are compounds which are inhibitors of SARS-CoV-2 main protease (Mpro), pharmaceutical compositions comprising such compounds, method for synthesizing such compounds and methods of using such compounds and compositions for the treatment, management or prevention of coronaviral related diseases.